Posted on

Big Bear Gold Corp. Announces Change of Transfer Agent to Olympia Trust Company

Vancouver, BC, Oct. 05, 2026 (GLOBE NEWSWIRE) — Big Bear Gold Corp. (TSXV: BEAR) (the “Company” or “BEAR”) announces that Olympia Trust Company has replaced Computershare Trust Company as the Company’s transfer agent effective October 1, 2026.  Shareholders do not need to take any action in respect to the change in transfer agent.

All inquiries and correspondence relating to shareholders’ records, transfer of shares, lost certificates, changes of addresses or other inquiries related to shares should now be directed to Olympia Trust Company as follows:

By sf-admin
Posted on

One Fridge-Sized Satellite. A Grounded Rocket Program. A Project That Won’t Launch Until 2027. James Altucher Says Elon Musk’s Rivals Aren’t Close.

A new free presentation from the tech expert who has called some of the biggest tech stories of the past two decades explains that everyone chasing Musk into space is years behind. 

A new free presentation from the tech expert who has called some of the biggest tech stories of the past two decades explains that everyone chasing Musk into space is years behind.

By sf-admin
Posted on

Type 2 Diabetes Market to Grow Significantly During the Forecast Period (2026–2036), with Rising Prevalence and Increasing Uptake of Next-Generation Therapies | DelveInsight

The type 2 diabetes market is expected to witness steady growth, driven by the rising global prevalence of diabetes, increasing rates of obesity and sedentary lifestyles, and growing awareness of early diagnosis and disease management. The expanding use of newer therapies, including GLP-1 receptor agonists, dual and triple incretin-based treatments, SGLT2 inhibitors, and other novel glucose-lowering agents, is further supporting market expansion. Additionally, the launch of emerging therapies such as agriSema (Novo Nordisk), Survodutide (BI 456906; Boehringer Ingelheim), Retatrutide (Eli Lilly), ASC30 (Ascletis Pharma), and others will further drive the market growth upward. 

The type 2 diabetes market is expected to witness steady growth, driven by the rising global prevalence of diabetes, increasing rates of obesity and sedentary lifestyles, and growing awareness of early diagnosis and disease management. The expanding use of newer therapies, including GLP-1 receptor agonists, dual and triple incretin-based treatments, SGLT2 inhibitors, and other novel glucose-lowering agents, is further supporting market expansion. Additionally, the launch of emerging therapies such as agriSema (Novo Nordisk), Survodutide (BI 456906; Boehringer Ingelheim), Retatrutide (Eli Lilly), ASC30 (Ascletis Pharma), and others will further drive the market growth upward.

By sf-admin
Posted on

G6 Hospitality and FBI Partner to Combat Human Trafficking

DALLAS, Oct. 05, 2026 (GLOBE NEWSWIRE) — G6 Hospitality, parent company of the Motel 6 and Studio 6 brands, has announced a nationwide partnership with the Federal Bureau of Investigation (FBI) to strengthen efforts to combat human trafficking across its hotel network. The partnership will focus on technology-driven prevention, intelligence sharing, employee and franchisee training, and closer collaboration with law enforcement agencies.

By sf-admin
Posted on

SPIE announces the acquisition of Clauser in France

Cergy, 5 October 2026 – SPIE, the independent European leader in multi-technical services in the areas of energy and communications, announces the acquisition of 94% of CLAUSER, a family-owned company with recognised expertise in industrial maintenance and high-power electrical installations.

By sf-admin
Posted on

SPIE annonce l’acquisition de CLAUSER en France

Cergy, le 5 octobre 2026 – SPIE, leader européen indépendant des services multi-techniques dans les domaines de l’énergie et des communications, annonce l’acquisition de 94% de CLAUSER, une entreprise familiale reconnue dans les domaines de la maintenance industrielle et des installations électriques à haute intensité.

By sf-admin
Posted on

National Advertising Division Finds Blissy Less Frizz Claim Supported; Recommends Certain Other Claims Be Modified or Discontinued

BBB National Programs’ National Advertising Division determined, as part of its routine monitoring program, that Blissy, LLC supported its “Less Frizz” claim for Blissy Silk Pillowcases in context, however, it recommended Blissy modify or discontinue certain claims concerning hair breakage and tangles, anti-aging and wrinkle prevention, acne, clinical study results, and dermatologist endorsements. 

BBB National Programs’ National Advertising Division determined, as part of its routine monitoring program, that Blissy, LLC supported its “Less Frizz” claim for Blissy Silk Pillowcases in context, however, it recommended Blissy modify or discontinue certain claims concerning hair breakage and tangles, anti-aging and wrinkle prevention, acne, clinical study results, and dermatologist endorsements.

By sf-admin
Posted on

Lanterne Dx Completes Merger with Flagship Biosciences, Expanding Biomarker and Digital Pathology Capabilities

Boulder, CO, Oct. 05, 2026 (GLOBE NEWSWIRE) — Lanterne Dx, LLC, a discovery and clinical phase CRO offering histopathology and biomarker validation services to pharmaceutical and biotech customers, today announced it has completed its merger with Flagship Biosciences, Inc., a computational biology, data science, and digital pathology company backed by Ampersand Capital Partners. The combined organization will operate under the Lanterne Dx name.

By sf-admin
Posted on

AIBotics Enters Definitive Defense-Technology Transaction with Patrick Tsang’s Empulser

Tsang joins AIBotics as Strategic Advisor ahead of contemplated CEO and director appointment upon closing, as Company moves to acquire the U.S.-focused Empulser defense-technology platform. 

Tsang joins AIBotics as Strategic Advisor ahead of contemplated CEO and director appointment upon closing, as Company moves to acquire the U.S.-focused Empulser defense-technology platform.

By sf-admin